Company Analysis

LB Pharmaceuticals Inc (LBRX)

Nasdaq: LBRX · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2016
Grade5.6
◀ Past 4.1● Present 6.1▶ Future 6.1
7 est.

Filings

92 filings since 2017 beside 50 insider forms · Non-accelerated filer and smaller reporting company and emerging growth company · read from EDGAR on Nov 13, 2026
Due nextNon-accelerated filer and smaller reporting company and emerging growth company
10-K Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends. by Mar 31, 2027
10-Q Quarterly report for the quarter ending Mar 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end. by May 15, 2027

A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 36 days after the quarter ended. The proxy statement was last filed Apr 23, 2026.

Filings a yearinsider forms included
1313166166
20172018202020222023202420252026

2026 counts to Nov 13, 2026.

Officer or director change (8-K item 5.02): 5 times in the last 36 months, the newest Sep 15, 2026.SEC letters: 9 in the last 36 months, the newest Apr 10, 2026.
Insider forms 50

Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.

FiledFormWhat it is, in plain wordsPeriodAsk
Nov 5, 2026 10-Q Quarterly report Sep 30, 2026
Nov 5, 2026 8-K items 2.02, 9.01 Results released · Current report
Oct 13, 2026 SCHEDULE 13G/A Large holder update, amended
Oct 5, 2026 EFFECT Registration effective
Oct 1, 2026 POS AM Registration amended after taking effect
Oct 1, 2026 S-3ASR Shelf registration
Sep 15, 2026 424B3 Shelf offering
Sep 15, 2026 8-K items 5.02, 7.01, 9.01 Officer or director change; Investor disclosure (Regulation FD) · Current report
Sep 3, 2026 424B3 Shelf offering
Sep 3, 2026 8-K items 5.02, 7.01, 9.01 Officer or director change; Investor disclosure (Regulation FD) · Current report
Aug 14, 2026 SCHEDULE 13G/A Large holder update, amended
Aug 11, 2026 424B3 Shelf offering
Aug 11, 2026 10-Q Quarterly report Jun 30, 2026
Aug 11, 2026 8-K items 2.02, 9.01 Results released · Current report
Jul 29, 2026 SCHEDULE 13G/A Large holder update, amended
Jul 29, 2026 424B3 Shelf offering
Jul 29, 2026 8-K items 1.01, 3.02, 7.01, 9.01 Major agreement signed; Shares sold without registration; Investor disclosure (Regulation FD) · Current report Jul 28, 2026
Jul 22, 2026 424B3 Shelf offering
Jul 22, 2026 8-K items 8.01, 9.01 Other event · Current report
Jul 16, 2026 SCHEDULE 13G Large holder notice
Jun 10, 2026 424B3 Shelf offering
Jun 10, 2026 8-K items 5.02, 9.01 Officer or director change · Current report Jun 8, 2026
Jun 9, 2026 424B3 Shelf offering
Jun 9, 2026 8-K item 5.07 Shareholder vote · Current report Jun 3, 2026
May 15, 2026 SCHEDULE 13G/A Large holder update, amended
May 15, 2026 SCHEDULE 13G Large holder notice
May 15, 2026 SCHEDULE 13G/A Large holder update, amended
May 13, 2026 SCHEDULE 13G/A Large holder update, amended
May 12, 2026 424B3 Shelf offering
May 12, 2026 10-Q Quarterly report Mar 31, 2026
May 12, 2026 8-K items 2.02, 9.01 Results released · Current report
Apr 23, 2026 ARS Annual report to shareholders Dec 31, 2025
Apr 23, 2026 DEFA14A Extra proxy material
Apr 23, 2026 DEF 14A Proxy statement Jun 3, 2026
Apr 14, 2026 EFFECT Registration effective
Apr 14, 2026 424B3 Shelf offering
Apr 10, 2026 CORRESP Reply to the SEC
Apr 10, 2026 UPLOAD SEC comment letter
Apr 6, 2026 S-1 Listing registration
Mar 26, 2026 S-8 Employee stock plan registration
40 of 92 shown

Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.

SI Assistanton LBRX · research, not advice